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Abstract
Background: In 2011, World Health Organization revised its recommendation for microbiological monitoring during
treatment for multidrug-resistant tuberculosis (MDR-TB) by increasing the frequency of culture examination from quarterly
to monthly after culture conversion. Implementing the recommendation requires substantial additional investment in
laboratory infrastructure. The objective of this review is to provide cost evidence that is needed for national TB programs to
budget for optimal monitoring strategies.
Methods and Findings: We conducted the first systematic literature review on unit cost estimates of three monitoring
strategies: 1) smear only; 2) culture only; 3) combined smear and culture. 26 peer-reviewed studies were selected by
searching 10 databases in English and Chinese for literature published between 1995 and 2012. Cost estimates were
converted into 2010 constant USD and international dollars. We assessed the quality of the estimates using a matrix with
five essential elements and provided a cost projection for the combined smear and culture tests where the data were
available. The 26 studies reported the cost estimates in 16 predominantly high- or middle-income countries from 1993 to
2009. The estimated unit cost for smear, culture, and combined tests ranges from $0.26 to $10.50, $1.63 to $62.01, and
$26.73 to $39.57, respectively. The ratio of culture to smear costs varies from 1.35 to 11.98. The wide range of estimates is
likely attributable to using different laboratory methods in different regions and years and differing practices in collecting
and reporting cost data. Most studies did not report information critical for generalizing their conclusions.
Conclusion: The paucity and low quality of unit cost estimates for TB monitoring in resource-poor settings impose technical
challenges in predicting the resources needed for strengthening microbiological monitoring. To improve the validity and
comparability of the cost data, we strongly advocate the data collection, estimation, and reporting follow protocols
proposed by WHO.
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Introduction
Management of multidrug-resistant tuberculosis (MDR-TB)
requires extensive monitoring of patients using bacteriologic
testing. This is necessary to evaluate interim response to treatment;
determine if patient isolation, regimen change, or adjunct therapy
is required; and to classify patient treatment outcomes. In order to
optimize the ability to detect non-response to treatment, recent
changes to World Health Organization (WHO) Guidelines for the
Programmatic Management of Drug-Resistant TB increased the
frequency of sputum culture monitoring from quarterly to monthly
after sputum culture conversion [1]. This recommendation was
the result of a systematic analysis, which observed increased delays
in detection of treatment failure with bi-monthly or quarterly
culture screening, and with exclusive reliance on smear [1]. The
available evidence, which was based on observational data and
modeling, is considered to be of low quality [2], implying that new
evidence would be very likely to change the recommendation.
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56074One important consideration of implementing the recommen-
dation is the increased cost required to assure monthly culture, in
addition to smear. This will require substantial additional invest-
ment in laboratory infrastructure since current capacity of
conventional laboratory is insufficient in many low-resource
settings. In 2010, eight of the 22 high-burden countries (HBCs)
that account for 80% of global TB cases did not meet the target of
one microscopy center per 100,000 people. Among the 36 countries
with the highest burden of TB and MDR-TB in the world, 20 had
less than the recommended capacity of one laboratory to perform
culture examination per 5 million people [3]. In order for national
TB programs to budget for implementation of optimal monitoring,
or to make decisionsabout the implementingalternative monitoring
strategies, information on costs of these strategies is essential.
Although new molecular tests have been validated and approved by
WHOfordiagnostic purposes[4],to date,these testshaveno role in
monitoring treatment. Consequently, this study focuses exclusively
on sputum smear microscopy and sputum culture for tuberculosis.
The purpose of this study is to provide cost estimates for the
different MDR-TB monitoring strategies recommended by WHO.
We conducted a systematic literature review of the published cost
estimates for three strategies to monitor bacteriologic response of
patients on MDR-TB treatment: 1) smear only; 2) culture only; 3)
combined smear and culture. Our objectives are to (1) provide a
comprehensive list of published cost estimates for the three testing
strategies, (2) assess the quality and limitation of the published cost
estimates, (3) project the cost of combined testing when data are
available, and (4) compare costs across monitoring schedules and
methods when data are available.
Methods
Literature Search Strategy
We searched the literature published in peer-reviewed journals
from 1995 to 2012 in both English and Chinese through 10
databases: Pubmed, Embase, Web of Knowledge, Health
Economic Evaluation and Database (HEED), Econlit, National
Health Service Economic Evaluation Database (NHSEED), Cost-
Effectiveness Analysis Registry (CEA), Research Papers in
Economics (RePEc), European Network of Health Economic
Evaluation Database (EURONHEED), China National Knowl-
edge Infrastructure (CNKI), Google Scholar and WHO. We also
searched grey literature from System for Information on Grey
Literature in Europe (OpenSIGLE), Healthcare Management
Information Consortium (HMIC) database, National Technical
Information Service (NTIS), and Biological Abstracts (BIOSIS).
We refined the search strategy in consultation with experts from
Harvard Countway Library of Medicine and used a combination
of three parts of keywords (e.g. ‘‘costs/economics/expenditure/
price’’, ‘‘Tuberculosis,’’ and ‘‘smear/culture/diagnosis/laborato-
ry’’) when searching through databases. The detailed key words
used in the search can be found in Table S1. The search was
conducted between 23 March and 25 April, 2012. Citations were
collected and managed electronically using EndNote X5. A total
of 475 citations were selected in the search. 107 duplicates were
automatically identified by EndNote and removed. This left a total
of 368 studies, which were screened in two phases (Figure 1). First,
we excluded 296 articles that did not contain cost information on
MDR-TB diagnosis strategies in their abstracts. In the second
phase, the full texts of the 72 remaining articles were evaluated
and 46 were excluded because they do not have specific cost
information for testing strategies. Our final study includes 26
articles [5–30]. One study [26] reported unit cost estimates for
three countries and we listed the estimates separately in results. No
protocol exists for systematic review of this topic.
Quality Assessment
We constructed a matrix to assess the quality of collected cost
estimates. In order for the cost estimates to be useful and
comparable, we sought at least the following information from
Figure 1. Study selection procedure for peer-reviewed literature from 1995–2012.
doi:10.1371/journal.pone.0056074.g001
Review of Costs for Smear and Culture Tests
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PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e56074each study: (1) the year of cost data being collected; (2) the level of
estimates (national or regional), (3) the specific diagnostic methods
and materials used; (4) the sources of data; and (5) the components
included in cost estimation. We treated each category as binary
and assigned values ‘‘0’’ or ‘‘1’’. For instance, if a study reported
the year of data being collected, ‘‘Data collection year’’ takes value
of 1, 0 otherwise. In tables and figures, we used publication year as
a proxy if the studies did not report information data collection
year. If the estimate is national, ‘‘National estimate’’ takes value 1,
0 otherwise. If test methods (such as light-emitting diode [LED],
Ziehl-Neelsen [ZN], etc) were reported in the paper, ‘‘Specifica-
tion of test methods’’ takes value of 1, 0 otherwise. If cost data
were directly collected from health facilities, ‘‘direct data sources’’
takes value of 1. If cost data were obtained from published price
list, ‘‘direct data sources’’ takes value of 0. If the cost components
included in estimating the unit cost of tests was reported by the
paper, ‘‘specification of cost items’’ takes value of 1, 0 otherwise.
We then summed the scores across the five categories for each
estimate with 0 representing the weakest quality and 5 the best.
When information was available, we also listed cost components in
Table 1 so the readers could identify which cost components were
included in cost estimation.
Projection of Unit Costs of Combined Smear and Culture
Tests
When smear and culture costs were reported separately in the
same study and the cost for combined tests was not available, we
imputed the unit cost of the combined tests by adding the unit
costs of the two testing strategies. The imputed value may serve as
an upper bound estimate for the combined test. Total costs for
combined tests may be lower than the imputed value due to a
single set of procedures being performed for both tests (e.g., for
sputum collection, transport, and processing). All cost estimates
were converted into 2010 constant USD using an exchange rate
and GDP deflator from International Monetary Fund [31]. To
adequately represent the distinction of costs across different
countries, the international dollar is preferable since it adjusts
the distortion effect of non-traded goods compared to single US$
value [32]. When detailed cost information was available to
identify the cost of traded and non-traded goods, we also
converted the cost estimates to 2010 international dollars using
purchasing power parity [33].
Analyzing Existing Data
When papers provided unit cost estimates for both the culture
and smear tests, we calculated the cost ratio of culture to smear.
For studies with the values of the cost components, we first
classified the components into two categories, traded and non-
traded goods, based on the definition from the WHO guideline for
cost-effectiveness analysis. Traded goods (e.g. equipment, supplies
and pharmaceuticals) are available on the international market
and available to all countries at an international market price.
Personnel, utilities, buildings and domestic transport are treated as
non-traded goods [32]. We then calculated the share of the two
types of goods in unit cost.
Results
Assessing Existing Studies
26 studies published between 1995 and 2012 reported cost
estimates in 16 countries (Table 1). Of these, 22 studies were
conducted in high-income or upper-middle income countries. Five
studies reported unit cost estimates in four low and lower-middle
income countries (India, Zambia, Kenya and Uganda) [26–30]. 17
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PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e56074of the selected studies reported unit cost estimates for smear test
alone. 19 studies reported unit cost estimates for culture test alone.
Five studies reported cost estimates for combined smear and
culture test in four middle-upper or high income countries.
The quality of reported data varied considerably among 26
studies. Five of them did not report which year the cost data were
collected, 12 of them reported national estimates, 14 of them
specified the methods used for test, 20 of them obtained data
directly from health facilities, and 13 of them provided the cost
components that were used to estimate of unit costs (Table 2).
Components of cost estimates were not reported in a standardized
way. Some studies only included costs for materials and overhead,
while others included costs on building, equipment, or even
patients’ spending on travel, food and income loss due to sick
leave. Using our quality scale, two studies scored 5 points, 11
studies scored 4, and 13 studies scored 3 or below (Table 2).
Cost Estimates
Estimated costs of smear microscopy, presented in Figure 2 in
constant 2010 USD, vary across countries from $0.26 in Tamil
Nadu, India (2002) [27] to $10.50 in Thailand (1996–1997) [16].
Unsurprisingly, unit costs for sputum smear differed in a given
country and year when different microscopy methods were used.
For example, in Cape Town, South Africa, unit costs for smear
with light-emitting diode (LED) microscopy and Ziehl-Neelsen
(ZN) in 2009 were $1.64 and $2.11 respectively [25].
The estimated unit cost for mycobacterial culture is between
$1.63 in Vladimir Oblast, Russia (2003) [19] and $62.01 in the
United Kingdom (2007) [9] (Figure 3). Estimates in the same
country and same year unsurprisingly vary when different media
were used and follow-up tests were required. For example, in
Brazil, unit costs of culture vary from $18.48 to $35.14 during the
same period (2006–2008). The former value is the cost per
Table 2. Quality assessment of the studies (1=yes; 0=no).
Author
1) Data collection
year
2) National
estimate
3) Specification
of test type
4) Direct data
source
5) Specification
of cost items Sum
Mueller et al. [28] 1 1 1 1 1 5
Sohn et al. [17] 1 1 1 1 1 5
Dowdy et al. [13] 1 0 1 1 1 4
Kamolratanakul et al. [16] 1 1 0 1 1 4
Balabanova et al. [20] 1 0 1 1 1 4
Menzies. et al. [5] 1 1 1 0 1 4
Sua ´rez et al. [18] 1 1 1 1 0 4
Vassall et al. (South Africa) [26] 0 1 1 1 1 4
Vassall et al. (India) [26] 0 1 1 1 1 4
Vassall et al. (Uganda) [26] 0 1 1 1 1 4
Whitelaw et al. [25] 1 0 1 1 1 4
Scherer et al. [14] 1 0 1 1 1 4
Chihota et al. [24] 1 0 1 1 1 4
Kivihya-Ndugga et al. [29] 1 0 1 1 1 4
Migliori et al. [8] 1 1 0 1 1 4
Albert [22] 1 0 1 1 0 3
Heymann et al. [10] 0 1 1 1 0 3
Muniyandi et al. [27] 1 0 0 1 1 3
Dinnes et al. [9] 0 1 1 0 0 2
WHO Policy Brief [19] 1 0 0 1 0 2
GA for TB Drug Development [12] 1 1 0 0 0 2
Rajalahti et al. [7] 1 0 0 1 0 2
Wurtz et al. [11] 1 0 0 1 0 2
Okello et al. [30] 1 0 0 1 0 2
Floyd et al. (Estonia) [6] 1 1 0 0 0 2
Hausler et al. [23] 0 0 0 1 0 1
Chen et al. [15] 0 1 0 0 0 1
Sinanovic et al. [21] 1 0 0 0 0 1
Floyd et al. (Tomsk Oblast) [6] 1 0 0 0 0 1
Notes: We treat each category as binary and assign values ‘‘0’’ or ‘‘1’’. 1) ‘‘data collection year’’: whether or not the data collection year was provided in the study. If yes,
‘‘data collection year’’=1, 0 otherwise; 2) ‘‘national estimate’’: whether or not the cost was estimated at national level. If yes, ‘‘national estimate’’=1, 0 otherwise; 3)
‘‘specification of test type’’: whether or not the test type was provided in the study, e.g. ZN/FM, MGIT/LJ. If yes, ‘‘specification of test type’’=1, 0 otherwise; 4) ‘‘direct
data source’’: whether or not the cost was directly collected from health facilities (e.g. hospital, clinic, laboratory etc.). If yes, ‘‘direct data’’=1, 0 otherwise; 5)
‘‘specification of cost items’’: whether or not the study described the components included in cost estimation. If yes, ‘‘specification of cost items’’=1, 0 otherwise. All the
studies are ranked by the summation of five scores from highest to lowest.
doi:10.1371/journal.pone.0056074.t002
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latter value is the cost per positive culture using MGIT for eight
patients per week [13].
Limited data were available for the cost of combined testing.
Results have only been reported in four countries and the values
ranged from $26.73 in Canada (2005–2006) [5] to $39.57 in USA
(1997) [10] (Figure 4). The imputed unit cost of combined tests
ranged from $2.27 in Vladimir Oblast, Russia (2003) [19] to
$48.23 in Thailand (1996–1997) [16]. The majority of imputed
estimates lies between $10 and $30.
The distribution of cost estimates for sputum smear is right-
skewed, with a median of $1.67 (Figure 5). The cutoff points for
the 25
th and 75
th percentiles are $1.21 and $2.54 respectively. The
median of cost estimates for culture tests is $18.48 with $11.08 as
the 25
th percentile and $33.33 as the 75
th percentile. For combined
testing, the median cost is $16.82, the 25
th percentile is $10.62 and
the 75
th percentile is $26.81.
12 studies reported cost estimates for both smear and culture
tests performed separately. The ratio of estimated costs for culture
to smear varies from 1.35 to 11.98 (Table 3); most are larger than
1.6, the ratio that has been used previously in the context of cost
and cost-effectiveness studies for drug-susceptible TB [34]. The
median ratio is 3.75. Notably, the ratio is available for only one
low-income (Uganda, 2011) [26] and one lower-middle income
country (India, 2011) [26]. Studies conducted between 1998 and
2011 in South Africa reported ratios from 2 to 11.98
[21,22,23,26].
Eight studies broke down estimated costs by traded inputs (i.e.
supplies and equipment) and non-traded inputs (such as labor). A
large variation is observed in the percentage of costs attributed to
traded inputs (Table 4): for smear tests, it ranges from 0.95% [16]
to 70.87% [17], and for culture test, it ranges from 21.16% [13] to
75.39% [20]. Unit cost estimates did not change significantly in
2010 international dollars (I$): I$ 1.34–19.24 for smear testing and
I$ 15.32–38.84 for culture testing.
Discussion
The existing unit cost estimates for smear, culture, and
combined smear and culture tests are very limited, especially in
low or lower-middle income countries. Nevertheless, a wide range
of published unit cost estimates was observed. For smear alone, the
estimated unit cost is between $0.26 and $10.5. For culture alone,
the estimated unit cost is between $1.63 and $62.01. For combined
Figure 2. Unit cost in 2010 USD for smear test alone. (1) Cost data were sorted by WHO regions: African Region (AFR), Region of the Americas
(AMR), Eastern Mediterranean Region (EMR), European Region (EUR), South-East Asia Region (SEAR) and Western Pacific Region (WPR). (2) For studies
with available information on test methods, we labeled them at the end of each bar. (3) [] indicates publication year when data collection year is not
available. (4) ZN: Ziehl-Neelsen; FM: fluorescence microscopy; LED: light-emitting diode.
a$1.16 is the average laboratory costs on 1000 subjects and
three specimens.
b$1.57 is the average laboratory costs on 1000 subjects and three specimens.
c$1.88 is the total cost $26.27 divided by 14 sputum
smears.
dSum of the overhead cost ($10.4) and the material cost ($0.1).
eFor the examination of three sputum specimens, the cost per patient
evaluated is $3.24 for FM and $3.59 for ZN.
fThe unit cost is the average over six regional estimates. For detailed information of the six regional
estimates, see Table S2.
doi:10.1371/journal.pone.0056074.g002
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and $48.23. Adjustment for purchasing power parity does not fully
explain the wide range of unit cost estimates we observed.
The wide variability of unit costs is partly due to using different
materials and methods in testing, or conducting the study in
different years or regions, partly due to non-standardized practice
in unit cost defining, data collecting, and reporting. For example,
for those with cost components available, the reported components
vary greatly across studies, from only including material and
overhead cost to covering the costs of building, equipment, and
even the spending of patients. Cost data were obtained from
different sources, including citing figures from a price list,
Figure 3. Unit cost in 2010 USD for culture test alone. (1) Cost data were sorted by WHO regions: African Region (AFR), Region of the Americas
(AMR), Eastern Mediterranean Region (EMR), European Region (EUR), South-East Asia Region (SEAR) and Western Pacific Region (WPR). (2) For studies
with available details on test methods, we labeled them at the end of each bar. (3) ‘‘[]’’ indicates publication year when data collection year is not
available. (4) LJ: Lo ¨wenstein-Jensen; MGIT: Mycobacteria Growth Indicator Tube; HLJ: Homemade Lo ¨wenstein-Jensen; CLJ: Commercially Lo ¨wenstein-
Jensen; MMGIT: Manually Mycobacteria Growth Indicator Tube; AMGIT: Automated Mycobacteria Growth Indicator Tube; FIND: Foundation of
innovative New Diagnostics; BD: Becton Dickinson.
a$7.08 is the average costs between negative and positive tests.
bThe paper indicates cost for
organism identification per positive culture on MGIT was $37.55 for using standard biochemical tests, $16.18 for anti-MPB64 assay and $2.38 for
cording; we added each of them to the cost per MGIT ($17.37) for calculating the cost for positive culture.
c$9.25 is the total cost of $85.07 divided by
9.2 sputum cultures.
dSum of the cost for sputum collection ($19.12) and the cost for bacterial culture ($19.99).
eSum of the overhead cost ($10.4) and
the material cost ($27.33).
fThe unit cost is the average over six regional estimates. For detailed information of the six regional estimates, see Table S2.
doi:10.1371/journal.pone.0056074.g003
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country, and aggregating data from all regions in a country. Non-
standardized cost estimates make it very difficult for cross-setting
comparison and making meaningful inference.
The quality of the estimates is a concern. About one fifth of the
selected studies did not even report the year in which cost data
were collected. Half of the selected studies did not specify test
methods (Migliori, or Kamolratanakul, or Qunfei, for example)
used in reported smear or culture tests. Almost half of the studies
did not report what components were included in cost estimation.
Since we know these factors have a significant bearing on cost
estimates, the lack of standardization–and low quality overall–in
cost data collecting and reporting present major challenges for
improving our knowledge of unit costs of various MDR-TB
monitoring strategies.
The calculated unit cost ratio for culture tests to smear tests
from existing studies is greater than the 1.6, a number which was
previously generated from cost data collected from a government
laboratory in South Africa [34]. The extent to which this ratio
varies between countries will likely depend on the relative weight
of non-traded inputs in the cost of each test. The cost of non-
traded inputs such a labour is more sensitive than the cost of
traded inputs to the income level of a given country. Therefore, if
the share of non-traded inputs in total cost is smaller for cultures
than it is for smears, we would expect the ratio to be higher in the
lowest income countries and lower in the highest income countries.
The new recommended strategy of monthly–rather than
minimum of quarterly–culture test after culture conversion, would
cost more. If smear and culture were done quarterly, only 6
combined tests would be required (in addition to 14 monthly
smears). According to the current recommendations of monthly
smear and culture, 20 combined tests would be required. Smear
and culture both have limited ability to predict poor treatment
response [1,35]. Culture, however, is much more accurate than
smear in detecting the presence of viable mycobacteria. Smear
microscopy sensitivity estimates range from 40 to 76%, with lower
sensitivity in children and HIV-coinfected patients [36–40]. As the
Guidelines note, ‘‘high value was placed on outcomes such as
preventing death, decreasing the transmission of MDR-TB that
could result from its delayed diagnosis, and avoiding increased use
of resources. [1]’’ Consequently, increased costs associated with
more frequent culture test may be justified because of the
Figure 4. Unit cost in 2010 USD for combined smear and culture test. (1) Directly obtained cost data are in red; imputed cost data are in
blue. (2) Cost data were sorted by WHO regions: African Region (AFR), Region of the Americas (AMR), Eastern Mediterranean Region (EMR), European
Region (EUR), South-East Asia Region (SEAR) and Western Pacific Region (WPR). (3) For studies with available details on test methods, we labeled
them at the end of each bar. (4) [] indicates publication year when data collection year is not available. (5) AFB: acid-fast bacillus; LJ: Lo ¨wenstein-
Jensen; MGIT: Mycobacteria Growth Indicator Tube.
aLaboratory running cost is $14.34. Estimated costs incurred by patients are $12.47 (assuming
that for taking an examination, a patient has to miss one-day work, take two-way transportation and have one meal outside).
b$31.55 is the total cost
of $94.66 divided by three combined smear and culture tests.
doi:10.1371/journal.pone.0056074.g004
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and the possibility of implementing interventions to avert them.
While it remains important for patients on treatment for MDR-TB
to have access to good quality culture for their proper monitoring,
our findings highlight a high cost difference between culture and
smear testing. It is noteworthy that one factor contributing to this
difference in low-resource setting may be the relatively infrequent
use of culture compared to smear at the time of data collection or
publication. These prices may be expected to decline once the
initial outlay associated with expanding culture laboratories has
been discounted.
Even within the same monitoring method, certain methodolog-
ical differences may result in cost differences, but also in sensitivity
and timing. For example, culture performed in liquid medium,
using the MGIT system is known to increase the detection of
viable mycobacteria over culture performed in solid LJ or Ogawa
medium, while decreasing from 8 weeks to 6 weeks the time
required to confirm a culture as negative. Although there was
additional cost associated with MGIT in at least 3 studies that
compared cost of culture in liquid and solid medium ([13], [24],
and [28]), these cost differences may be justified since they
accelerate the time to detection and intervention and increase the
sensitivity of the test. There are similar differences among the cost
and sensitivity of smear microscopy methods [40].
Lastly, three studies ([13], [22], and [24]) reported variation in
unit cost of culture depending on whether the result was negative
or positive. This highlights another possible source of variability in
estimates that was not explicitly reported in the other studies.
This study is the first systematic review of cost estimates for tests
commonly used to monitor MDR-TB treatment. We reviewed the
Figure 5. Summary of estimates of the three types of tests. (1) In
each boxplot, dots represent outliers which are beyond the interval of
(Q1–1.5*IQR, Q3+1.5*IQR): Q1 is the 25
th percentile, Q3 is the 75
th
percentile, IQR is the interquartile range (75%–25%). (2) The five values
listed beside each boxplot represent upper adjacent value (maximum
value after excluding outliers), 75
th percentile, median (50%), 25
th
percentile, and lower adjacent value (minimum value after excluding
outliers), respectively. For instance, in Plot 5a, for estimates of smear test
alone, $3.54 (upper adjacent value) is the maximum value excluding
threeoutliers. $2.54isthe valueatthe75
thpercentile.$1.67isthevalueof
median. $1.21 is the value at the 25
th percentile. $0.26 (lower adjacent
value) is the minimum value excluding outliers. (3) For Plot 5c, the
estimates of combined test include the imputed values.
doi:10.1371/journal.pone.0056074.g005
Table 3. Ratio of unit cost for culture to smear.
Author Site Time period Ratio of culture to smear Methods on smear/culture
Scherer et al. [14] Brazil 2003–2004 1.35 ZN (S)
Sinanovic et al. [21] South Africa 1998–1999 2
a Not available
Migliori et al. [8] Italy 1995 2.02 Not available
Menzies et al. [5] Canada 2005–2006 2.22 Liquid media (C)
Albert [22] South Africa 2003 2.3 ZN (S); BACTEC 460TB (C), (2)
Hausler et al. [23] South Africa [2005] 2.32 Not available
WHO Policy Brief [19] Russia 2003 2.58 Not available
Floyd [6] Estonia 2001–2002 2.75 Not available
Kamolratanakul et al. [16] Thailand 1996–1997 3.6
b Not available
Menzies et al. [5] Canada 2005–2006 3.89 Solid+liquid media (C)
Albert [22] South Africa 2003 4.38
c ZN (S); BACTEC 460TB (C), (+)
Sua ´rez et al. [18] Peru 1997–1999 4.93 ZN (S); LJ (C)
Floyd [6] Tomsk Oblast 2001–2002 5.2 Not available
Chen et al. [15] China [2011] 5.61 Not available
Vassall et al. [26] Uganda [2011] 9.47 LED (S); LJ (C)
Vassall et al. [26] India [2011] 9.67 LED (S); LJ (C)
Vassall et al. [26] Uganda [2011] 11.61 LED (S); MGIT (C)
Vassall et al. [26] South Africa [2011] 11.98 LED (S); MGIT (C)
S: smear test alone; C: culture test alone; ZN: Ziehl-Neelsen; (+): positive result; (2): negative result; TB: tuberculosis; LJ: Lo ¨wenstein-Jensen; LED: light-emitting diode;
MGIT: Mycobacteria Growth Indicator Tube.
aThe original unit cost for culture is the average cost between negative and positive tests;
bThe original unit cost for culture includes the cost for sensitivity testing;
cThe original unit cost for positive culture includes the cost for MDR-TB identification.
doi:10.1371/journal.pone.0056074.t003
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TB after India and the availability of Chinese cost data provides
critical information for scaling up the monitoring tests for this large
at-risk population. Using existing cost data, we also projected the
unit cost of combined tests which could serve as useful reference to
policy makers.
We propose a framework for evaluating the quality of unit cost
data for TB monitoring tests. The five categories included in the
quality score are crucial for determining the generalizability and
validity of the cost data. They, may not, however, cover all
important aspects. For instance, we only distinguished between the
availability and absence of cost components, but did not consider
the comprehensiveness of cost components. We assigned each
category with the same weight and this may oversimplify the
evaluation.
The paucity and low quality of unit cost estimates for TB
monitoring in developing countries impose technical challenges in
predicting the resource needed for strengthening microbiologic
monitoring. As new molecular tests are being rapidly introduced
globally to diagnose patients with presumptive TB and drug-
resistant TB in one step, evaluation of the costs associated with the
change in diagnostic practices – which was not the object of this
paper - will be necessary. High quality cost data is especially
important for the regions with high incidence of tuberculosis and
MDR-TB, where scarce resources must be allocated efficiently.
We strongly advocate that more data are collected from these
regions, and that cost data collection, estimation, and reporting
should follow the protocols proposed by the WHO [34] to improve
the validity and comparability.
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